SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GME is trending as some traders draw comparisons to BYND's recent surge, speculating whether GME could see a similar short squeeze; the community is actively discussing prior squeezes and potential catalysts. Some investors express frustration with GME's performance, while others remain optimistic about its long-term potential amid growing discussions around meme stocks and short squeeze opportunities.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread reports of users experiencing outages and technical issues, sparking frustration and concerns about the platform's reliability; some users are unable to access their accounts or execute trades. The issues are reportedly tied to a larger Amazon Web Services (AWS) outage, but the community is still expressing distrust and considering alternative platforms. Despite the technical difficulties, the stock price is up, leading to confusion and speculation about market manipulation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's upcoming earnings and Elon Musk's compensation plan are driving much of the current discussion. Community members are actively debating potential earnings outcomes, forward guidance, and the impact of Musk's pay package on shareholder value and stock performance. Additionally, some traders point to technical indicators and unusual options activity as potential signals for the stock's direction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions about AI competition and its potential impact on Google's search dominance, with investors weighing the implications of new AI browser technologies. Community members are also focused on Google's AI investments and potential partnerships, particularly regarding its cloud infrastructure and Gemini AI model. Positive analyst ratings and potential earnings run-ups are contributing to the stock's current momentum.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to renewed community interest, possibly driven by its recent surpassing of a one-year high and BTIG adjusting their stance to a Buy rating with a target price of $40. Community members are actively discussing potential catalysts and upcoming opportunities related to the stock's momentum. The company's focus on novel therapies for immune-related diseases and recent financing updates may also contribute to the heightened attention.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong earnings and procedure growth, particularly with the da Vinci 5 system. The community is weighing the impact of tariffs and margin pressures against the company's long-term growth potential and market dominance in robotic surgery. Bullish sentiment is fueled by raised guidance and analysts' price targets, while some caution against high valuation and potential market volatility.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a mixed Q3 earnings report and cautious forward guidance, sparking concerns about the near-term outlook despite a strong analog chip performance. Community discussions center on whether this drop represents a buying opportunity or signals deeper industry headwinds, with some analysts questioning the capital expenditure plan. Investors are also monitoring tariff implications and potential shifts in market share amid evolving US-China trade dynamics.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$NERV is trending due to a significant financing deal aimed at advancing its schizophrenia treatment through Phase 3 trials, sparking excitement among retail investors. Community discussions revolve around the potential FDA catalyst and the stock's potential for further gains. The stock's substantial pre-market surge and high trading volume reflect the market's reaction to the news and the renewed focus on the company's prospects in the biotech sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the company announced it will acquire Railbird and launch DraftKings Predictions, expanding into regulated prediction markets beyond sports betting, potentially impacting finance and entertainment; the community is actively discussing whether this move will be a success and if DraftKings can compete in this space, particularly with concerns about market share and regulation.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags ($FUN) is trending after NFL star Travis Kelce reportedly teamed up with activist investor Jana Partners to push for company changes. The community speculates about potential marketing strategies involving Kelce's fiance, Taylor Swift, while some express skepticism about the company's long-term prospects despite the recent investment news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated with its Revita lost an additional 2.5% of their total body weight at three months in a trial. At the time of writing, shares of the company traded 28% higher on Friday afternoon.The study was designed to evaluate the Revita procedure in adults with obesity who achieved at least 15% total body weight loss with Tirzepatide, the active ingredient in Eli Lilly’s blockbuster weight loss drug Zepbound. Those who received a sham procedure after discontinuing Zepbound regained 10% total body weight in the study at three months, the company said.Revita is Fractyl’s lead product candidate. The procedure is designed to reverse damage to intestinal nutrient-sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets by remodeling the inner wall of the first part of the small intestine.“These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible,” the company said, while adding that the study also supports Revita in post-GLP-1 weight maintenance.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156942/0/en/Fractyl-Health-Announces-Groundbreaking-Data-from-REMAIN-1-Midpoint-Cohort-Showing-Revita-Maintained-Weight-Loss-After-GLP-1-Discontinuation.html">stated</a> that no serious adverse events related to Revita were identified in the study, and side effects were infrequent and mild. The firm expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.On Friday, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156951/0/en/Fractyl-Health-Announces-Pricing-of-60-Million-Underwritten-Offering-of-Common-Stock.html">announced</a> the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, representing a discount of about 1% from the stock’s closing price on Thursday. The gross proceeds from the offering are expected to be about $60 million, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GUTS">GUTS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_00_54_PM_png_90a4342a59.webp" alt="GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment at the offering.<stembedurl>https://stocktwits.com/Stmkr/message/630122910</stembedurl>GUTS stock is down 38% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GUTS Stock Rallied About 28% Today – Here’s Why

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.

Equity

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.


Fractyl Health shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants.&nbsp;The offering includes accompanying common warrants, and Ladenburg Thalmann is acting as&nbsp;the sole book-running manager.Despite the market’s negative reaction to the capital raise, retail sentiment on Stocktwits remained optimistic, buoyed&nbsp;by the release of strong new clinical data hours earlier.&nbsp;The company shared two-year follow-up results from the Germany Real-World Registry study, which evaluated the Revita procedure in people with obesity and advanced type 2 diabetes (T2D) who had inadequately controlled glucose levels despite being on up to three glucose-lowering agents (GLAs).According to the study, a single Revita procedure led to a median weight loss of 9.6%, sustained over two years, with weight decreasing from 104 kg to 97 kg at year one and remaining stable through year two.&nbsp;Notably, 7 of 8 participants achieved at least a 5% weight reduction, and 5 of 8 saw reductions of 10% or more. Only one participant, who had a history of cortisone therapy known to cause weight gain, experienced&nbsp;a modest weight increase.Meanwhile, median HbA1c decreased from 9.6% to 7.2%, which was maintained over two years of follow-up. Patients were also able to reduce or stabilize the dosing of GLAs, and there were no device or procedure-related serious adverse events.Fractyl said the findings support the potential of Revita as a long-lasting, non-drug metabolic therapy and build momentum for its ongoing U.S. pivotal trial, REMAIN-1, which is under an IDE and is designed to assess Revita for weight maintenance after GLP-1 treatment.&nbsp;The company expects Midpoint Cohort data in the third quarter and primary endpoint data from the Pivotal Cohort in the second half of&nbsp; 2026.As of now, 34 patients are enrolled in the Germany registry, which is no longer recruiting but will continue with protocol-defined follow-up. Weight loss and glycemic benefits were observed as early as one month post-procedure and persisted throughout the study duration.Fractyl intends to use net proceeds from the offering, along with existing cash, to support both the Revita and Rejuva pipeline programs, and for working capital and general corporate purposes.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">retail sentiment for Fractyl</a> was ‘extremely bullish’ amid a 124% surge in 24-hour message volume.One user said the strong two-year Revita data was a “big win” and that similar setups, including positive clinical news followed by a quick offering, have historically seen shares recover to pre-offering levels.&nbsp;While the user noted the company “could have done the PR’ing/offering a bit better,” they added the underlying science was “phenomenal” and called Revita a “first-in-class” product with major potential.<stembedurl>https://stocktwits.com/BioRich/message/623885253</stembedurl>Another user said they were buying into Fractyl, looking for either a short squeeze or a potential buyout.<stembedurl>https://stocktwits.com/garygb/message/623881828</stembedurl>Fractyl’s stock has declined 12.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Fractyl Health (GUTS) shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants. (Photo credit: Getty Images)

Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data

Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health Receives FDA IDE Approval for the Revita  Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study

Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTS  Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.32	--	--	N/A
Q2 '25	-$0.36	--	--	N/A
Q1 '25	-$0.48	-$0.47	1.40%	BEAT
Q4 '24	-$0.44	-$0.52	-19.54%	MISSED
Q3 '24	-$0.50	--	--	N/A

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest GUTS News

GUTSFractyl Health Inc.